Anandamide (AEA) is an endogenous ligand of cannabinoid receptors and a wellcharacterized mediator of many physiological processes including inflammation, pain, and appetite. The biosynthetic pathway(s) for anandamide and its N -acyl ethanolamine (NAE) congeners remain enigmatic. Previously, we proposed an enzymatic route for producing NAEs that involves the double-O -d e a c y l a t i o n o f N -acyl phosphatidylethanolamines (NAPEs) by alpha-beta hydrolase 4 (ABDH4 or Abh4) to form glycerophospho (GP)-NAEs, followed by conversion of these intermediates to NAEs by an unidentified phosphodiesterase. Here, we report the detection and measurement of GP-NAEs, including the anandamide p r e c u r s o r g l y c e r o p h o p s p h o -Narachidonoylethanolamine (GP-NArE), as endogenous constituents of mouse brain tissue. Inhibition of the phosphodiesterasemediated degradation of GP-NAEs ex vivo resulted in a striking accumulation of these lipids in brain extracts, suggesting a rapid endogenous flux through this pathway. F u r t h e r m o r e , w e i d e n t i f y glycerophosphodiesterase 1 (GDE1), also known as MIR16, as a broadly expressed membrane enzyme with robust GP-NAE phosphodiesterase activity. Together, these data provide evidence for a multi-step pathway for the production of anandamide in the nervous system by the sequential actions of Abh4 and GDE1.
N-acylated ethanolamines (NAEs) were first isolated from preparations of egg yolk, peanut oils, and soybeans in the 1950s due to their anti-inflammatory and anti-allergenic properties (1) . In the ensuing decades, NAEs have been found in nearly all mammalian tissues and ascribed a number of bioactivities (2) . Studies by Schmid and colleagues first identified N-acylated phosphatidylethanolamines (NAPEs) as markers of ischemic shock in brain and heart tissues and postulated that these lipids were the metabolic precursors of NAEs (3) . In 1992, anandamide (N-arachidonoyl ethanolamine, NArE, AEA), was identified as an endogenous ligand for the brain (type I) cannabinoid receptor (4) . The discovery of AEA as an endocannabinoid sparked renewed interest in NAE biochemistry and a search for pathways responsible for NAE biosynthesis and degradation. The integral membrane protein fatty acid amide hydrolase (FAAH) has been identified as the primary enzyme responsible for NAE degradation in most tissues, including brain (5) . Pharmacological (6) or genetic (7) blockade of FAAH leads to elevated NAE levels and anti-inflammatory and analgesic effects mediated through cannabinoid receptors. Despite these advances, a detailed understanding of the biosynthetic pathway(s) for NAEs has proven more elusive.
Substantial evidence implicates NAPEs as the key metabolic precursor for NAEs. NAPEs are formed by the calcium-dependent transfer of an acyl chain from the sn-1 position of phosphatidylcholine to the amine of phosphatidylethanolamine by an asof-yet unidentified enzyme (8) . N-Arachidonoyl NAPE, which serves as the AEA precursor, is found at very low levels in brain tissue, consistent with the low abundance of arachidonate in the sn-1 position of phosphatidylcholine (9) . Recently, a calciumindependent transacylase capable of generating NAPE from PE and PC was cloned, however this protein displays markedly different properties from the brain enzyme that generates NAPEs (10) .
Release of NAEs from NAPEs was originally postulated to occur via a calciumstimulated D-type phospholipase (PLD). In 2004, Ueda and colleagues isolated and identified an NAPE-selective PLD (NAPE-PLD) (11) . Mice with a disrupted NAPE-PLD gene [NAPE-PLD(-/-) mice] were found to exhibit dramatically reduced brain levels of long chain, saturated NAEs. In contrast, polyunsaturated NAEs, including AEA, were unaltered in these animals (12) . These results indicate that enzymes distinct from NAPE-PLD are involved in the biosynthesis of AEA in vivo. Consistent with this premise, RNA interferencemediated knockdown of NAPE-PLD in RAW264.7 macrophages failed to alter AEA levels in these cells (13) .
That NAPE-PLD does not appear to contribute to AEA biosynthesis, at least in certain cell and tissue types, necessitates the existence of alternative biosynthetic enzymes. Consistent with this premise, substantial rates of conversion of NAPE to NAE were observed in tissue extracts from NAPE-PLD(-/-) mice (12) . Interestingly, this residual activity was not due to another D-type phospholipase, but rather to a multi-enzyme cascade that involves the initial A/B-type phospholipase-catalyzed double O-deacylation of NAPEs to generate glycerophospho-(GP)-NAEs, followed by phosphodiesterase-catalyzed conversion of these intermediates to NAEs (Figure 1 ). This pathway was further found to be inhibited by millimolar concentrations of calcium which may explain why it had previously gone undetected in assays for NAPE-PLD activity that included high (2-10 mM) levels of exogenous calcium. Conventional protein chromatography coupled with activitybased proteomic analysis identified the hitherto unannotated enzyme alpha/beta-hydrolase 4 (Abh4 or ABHD4) as a B-type NAPE lipase capable of removing both O-acyl chains from NAPE to yield GP-NAE (14). This finding s u g g e s t e d t h a t g l y c e r o p h o s p h o -Narachidonoylethanolamine (GP-NArE) may be a physiologically relevant precursor of AEA and pointed to the GP-NAE phosphodiesterase as a critical final step leading to AEA release. However, to our knowledge, GP-NAEs have not previously been identified as natural brain constituents, nor has a phosphodiesterase capable of converting these lipids to NAEs been characterized. Herein, we describe the detection and measurement of GP-NAEs, including the AEA precursor GP-NArE, as endogenous brain constituents. We observe the enzymatic formation of endogenous GP-NAEs in ex vivo brain preparations and, moreover, we identify t h e i n t e g r a l m e m b r a n e e n z y m e glycerophosphodiesterase 1 (GDE1) as a GP-NAE phosphodiesterase enriched in brain that is capable of generating NAEs, including AEA, in vitro.
EXPERIMENTAL PROCEDURES
Materials-1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine was purchased from Avanti Polar Lipids (Alabaster, AL Synthesis of GP-NAE standards and substrates was performed essentially as described (14) . Briefly, acid chlorides were reacted with an excess of 1-oleoyl-2-hydroxy-sn-g l y c e r o -3 -phosphoethanolamine and allowed to react for 1 h in CH 2 CL 2 with a catalytic amount of triethylamine. N-acylated lipids were then purified by silica-gel flash column chromatography. The resulting lysoNAPE was stirred vigorously in 2 4 OH. Analysis was performed with an ESI source in the negative ionization mode with a source-voltage of -3.5 kV, flow-rate of 0.4 mL/min and capillary temperature of 325 °C. Care was taken to avoid carryover by running 'blank' samples prior to all endogenous measurements. The method included a highresolution full-scan in the Orbitrap (operated at 30,000 resolution) followed by six fragmentation events in which fragment-ions were analyzed in the ion-trap and/or sent to the Orbitrap for high-resolution mass analysis depending on the experiment. Fragmentation events were chosen to detect palmitoyl-, oleoyl-, arachidonoyl-, eicosanoyl-, docosahexaenoyl-, and pentadecenoyl-GP-NAEs by targeting m/z values of 452, 478, 500, 508, 524, and 436, for MS/MS analysis, respectively. For quantitation extracted ion chromatograms of the phospho-NAE peaks ([M-H-74] -)were integrated and compared to the internal N-C15:1 GP-NAE standard. Extractions using synthetic standards revealed extraction-efficiencies of 3%, 25%, 45%, 8%, 18%, and 77% for N-C15:1, C20:4, C22:6, C16:0, C18:1, and C20:0 GP-NAEs, respectively, and measurements of endogenous GP-NAEs were corrected accordingly. Subcloning and recombinant expression of GDE-domain containing enzymes-T h e following ESTs were purchased from OpenBioSystems (Huntsville, AL) and subcloned into pcDNA3.1-myc/His using conventional techniques:
GDE1/MIR16 -IMAGE:3601420, GDE2 -IMAGE: 4224574, GDE3 -IMAGE: 4457335, GDE4 -IMAGE:3602449, GDE7: 3486726. COS-7 cells were grown at 37°C with 5% CO 2 to ~70% confluence in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum in 10-cm dishes and transfected with 6 µg of plasmid DNA using the FuGENE 6 (Roche Applied Science) transfection reagent according to the manufacturer's protocol. After 48 h, the cells were washed twice with phosphatebuffered saline, scraped, resuspended in 50 mM Tris pH 8.0, and sonicated to lyse. The lysates were then spun at 145,000 x g for 45 min to isolate the insoluble (membrane) fraction, which was sonicated to resuspend in 50mM Tris pH 8.0. Cell-membranes thus prepared were stored as single-use aliquots at 0.01 mg/mL for enzyme assays or 2 mg/mL for western blots at -80°C. For western blots the cellmembranes were treated with (or without) PNGase F (New England Biolabs, Ipswich, MA) according to the manufacturer's protocol prior to SDS-PAGE analysis. GP-NAE phosphodiesterase activity assay-Enzyme assays were performed in 4 mL glass vials in 50 mM Tris pH 8.0 with 2 mM MgCl 2 except for the following experiments. pH-rate profiles were performed in a buffers containing 50 mM Tris, 50 mM HEPES, and 50 mM glycine that was adjusted with HCl to the desired pH. The cation-sensitivity assays were performed in 50 mM Tris pH 8.0 and the indicated cation (or EDTA) at 2 mM final concentration. For all assays, 10 µL protein (100 µg for cell-membranes or 500 µg for brain samples) was added to 85 µL of the specified buffer and 5 µL GP-NAE substrate (2 mM in DMSO or EtOH, 100 µM final concentration). Vials were incubated at 37°C
for 30 min and then quenched with 1.5 mL 2:1 CHCl 3 :MeOH and 400µL 1% formic acid. For LC-MS assays, d 4 -N-oleoylethanolamine (10 µL of 100 µM stock in EtOH; 1 nmol total) was added as an internal standard. Phases were separated by centrifugation at 1,400 x g for 3 min and the organic phase transferred to a new vial and evaporated to dryness under a stream of N 2 . For LC-MS assays the dried reactions were resuspended in 500 µL MeOH and 50 µL injected into an Agilent 1100-series LC-MS for analysis using an 8-minute gradient from 30% to 100% buffer B. Buffer A consisted 5:95 MeOH:H 2 O with 0.1% formic acid and buffer B consisted of 5:35:60 H 2 O:MeOH:iPrOH with 0.1% formic acid. NAE formation was quantified by comparison with the internal d 4 -N-oleoylethanolamine standard. For radiochromatographic assays, the dried reactions were dissolved in 20 µL of 2:1 CHCl 3 :MeOH, spotted on thin layer silica plates, and developed in 40:10:1 CHCl 3 :MeOH:28% NH 4 OH. Distribution of radioactivity on the plate was quantified by a phosphorimaging device (Packard), and products were identified by comparison with from percentage values of the total radioactivity on the TLC plates. All of the assays were conducted with n=2 or 3, and error bars represent the standard error of the mean. Generation of polyclonal antibodies against mGDE1 and western blotting-Polyclonal antibodies that recognize GDE1 were prepared by expressing an N-terminal GST-fusion of the C-terminal 163 amino acids of GDE1 prepared using traditional subcloning techniques. This fusion protein was expressed in BL21-DE3 cells by growing at 37 °C to OD 600 = 0.4 and inducing expression with 1 mM isopropyl β -D-1-thiogalactopyranoside (IPTG). After 4 h, cells were harvested and sonicated. Lysate was centrifuged for 30 min at 12,000 x g and the pellet was resuspended in phosphate buffered saline and visualized by SDS-PAGE and protein staining. The fusion protein was excised from the gel, homogenized, mixed 1:1 with RIBI adjuvant, and injected three times into rabbits at two-week intervals. One week after the final injection, blood was taken and antibodies affinity purified with the original antigen immobilized on PVDF membrane. These polyclonal antibodies were used at a 1:200 dilution in TBST (20 mM Tris-HCl, 150 mM NaCl, 0.2% Tween-20) overnight at 4 °C followed by incubation with secondary HRPconjugated goat anti-rabbit (Bio-Rad Laboratories, Hercules, CA) at 1:5000 in TBST prior to developing with chemiluminescent ECL substrate (Pierce, Rockford, IL) and exposing to X-ray film. Specificity of antibodies was tested via immunoblots of mock-and GDE1-transfected COS-7 cell membranes (Supplemental Figure 1) . Reverse Transcription-PCR-cDNA was prepared using the Superscript III reverse transcriptase kit (Invitrogen) according to the manufacturer's protocol. PCR was performed using 30 cycles with cycling times of 30 s of melting at 95° C, 30 s of annealing at 58° C, and 30 s of extension at 72° C with Taq DNA polymerase using the following primers: GDE1 o l i g o n u c l e o t i d e s , 5 ' -CCGACTATGTGATCTGACATTTGAACAA G T T A G G -3 ' a n d 5 ' -CCATACTGTTATTGTACAGCTGTGGAAAT TCCG-3'; and glyceraldehyde-3-phosphate d e h y d r o g e n a s e oligonucleotides, 5'-TGTCTTCACCACCATGGAGAAGGC-3' and 5'-TGGCAGTGATGGCATGGAACTGTGG-3'. The products were visualized on a 2% agarose gel. -transition, several endogenous GP-NAEs, including C16:0, C18:1, and C20:4 GP-NAEs, could be detected that displayed identical retention and fragmentation to synthetic standards (Table 1 and Figure 2 ). Parent and fragment mass signals were strongest for the more abundant GP-NAEs (C16:0, C18:1) ( Figure  2 ), but could be detected for all GP-NAEs listed in Table 1 . Furthermore, we employed a hybrid iontrap/Orbitrap instrument, which enabled highresolution mass measurements of parent and fragment-ions. This instrument yielded measurements of endogenous GP-NAEs and key fragments that were within ~2 ppm of predicted masses thereby confirming the identity of these NAE precursors (Supplemental Table 1 ). Quantification of endogenous GP-NAEs was performed by comparison to an internal unnatural (N-C15:1) GP-NAE standard.
RESULTS

Measurement of endogenous GP-NAE-
Endogenous GP-NAEs were present at levels somewhat lower than endogenous NAEs ( Table 1) .
Due to the low levels of endogenous GPNAEs, we sought additional evidence that these lipids represented potential intermediates in the enzymatic biosynthesis of NAE. To measure enzymatic turnover of GP-NAEs we employed an ex vivo assay. Previous studies had determined that brain GP-NAE phosphodiesterase activity was inhibited by EDTA (14) . Here, we found that treatment of brain extracts with EDTA resulted in dramatic accumulation of endogenous GPNAEs in brain homogenates over time ( Figure  3A) . Methoxy arachidonoylfluorophosphonate (MAFP) is a general inhibitor of serinehydrolases including the NAPE-lipase Abh4 (14) . The accumulation of GP-NAEs was completely blocked by addition of MAFP thereby confirming that these lipids originated from the enzymatic sn-1/sn-2-deacylation of NAPE precursors. Notably, long chain saturated GP-NAEs (e.g., C20:0) did not accumulate, suggesting that this pathway may only be active on GP-NAEs bearing select N-acyl chains (see Discussion). The rapid enzymatic turnover of GP-NAEs in brain extracts, combined with the low endogenous levels of these precursors, suggests that they represent transient intermediates in the biosynthesis of NAEs.
The significant accumulation of the AEA precursor C20:4 GP-NAE in EDTAtreated brain extracts permitted acquisition of much cleaner MS profiles for this lipid, which matched precisely those observed with a synthetic standard ( Figure 3C and D) .
Identification of GDE1 as the GP-NAE phosphodiesterase-Having confirmed that GPNAEs are endogenous constituents of mouse brain, we next attempted to identify the enzyme(s) that catalyze hydrolysis of the phosphodiester bond of these lipids to release NAEs. One candidate enzyme class is the glycerophosphodiester-phosphodiesterases (GDEs), which hydrolyze the phosphodiester bond of glycerophosphodiesters to yield glycerol phosphate and an alcohol (16) . Enzymes containing this GDE domain have been shown to play roles in glycerophospholipid metabolism in yeast and bacteria (17) . Searches of mammalian genomes revealed 7 genes encoding proteins containing GDE domains. The GP-NAE phosphodiesterase activity in brain tissue was found exclusively in the membrane fraction ( Figure 5B ) and treatment with NaCl or Na 2 CO 3 did not solubilize the activity (not shown), indicating that it derives from an integral membrane protein. Of the seven genes encoding mammalian GDE-domain containing proteins, six are predicted to have transmembrane domains and of these, only five are expressed in brain, as determined by EST counts from the UniGene database and reports from the literature (18) . These five predicted GDEs were heterologously expressed in COS-7 cells as epitope-tagged proteins. Following confirmation of expression by western blotting, membrane fractions from these cells were tested for GP-NAE phosphodiesterase activity using an LC-MS-based substrate assay with synthetic N-C16:0 GP-NAE. One enzyme, GDE1, displayed robust GP-NAE phosphodiesterase activity, while the other four GDEs were indistinguishable from a mocktransfected control ( Figure 4A and B) .
Brain GP-NAE phosphodiesterase and recombinant GDE1 exhibit similar biochemical properties-We next compared the activity of GDE1 to the GP-NAE phosphodiesterase activity detected in mouse brain. First, we confirmed by western blotting that GDE1 ( Figure 5A ), like the GP-NAE phosphodiesterase activity, resides in brain membrane fractions ( Figure 5B) . Treatment with the glycosidase PNGaseF reduced the apparent molecular mass of GDE1 by ~5 kDa, indicating that, as previously reported, the enzyme is an N-linked glycoprotein (19) . These data are consistent with hydropathy plot analyses that predict the enzyme is an integral membrane protein with the majority of the protein sequence, including the catalytic domain, facing the luminal/extracellular compartments of the cell. We next compared the sensitivity of GDE1 and brain GP-NAE phosphodiesterase to various divalent cations and found that both activities were inhibited by EDTA, calcium chloride, and zinc chloride, and markedly enhanced by magnesium chloride (Figure  6 B ) . Recombinant GDE1 and brain GP-NAE phosphodiesterase activity also displayed equivalent pH-rate profiles, showing a slightly alkaline pH optimum ( Figure 6A) . Finally, GDE1 and GP-NAE phosphodiesterase activity were found to exhibit nearly identical tissue distributions, with highest levels being observed in brain and spinal cord, followed by kidney, liver, and testis ( Figure 7) . In contrast, little or no GP-NAE phosphodiesterase activity or GDE1 expression was detected in heart or spleen. Interestingly, this tissue distribution resembles that of other enzymes that participate in NAE metabolism, including FAAH (5) and Abh4 (14) . These data collectively suggest that GDE1 is a principal GP-NAE phosphodiesterase in mammalian tissues.
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Finally, we measured the ability of GDE1 to hydrolyze GP-NAEs with various Nacyl chains. GDE1 was able to generate NAEs from synthetic GP-NAEs bearing multiple types of N-acyl chains, showing the highest activity with C16:0, C18:1, and C20:4 substrates, and lower activity with C20:0 and C22:6 substrates ( Figure 8) .
DISCUSSION
Despite over 20 years of study, the biosynthesis of AEA and other NAEs remains poorly understood (20) . It is generally accepted that N-acyl phosphatidylethanolamines (NAPEs) are the precursors for NAEs, but the precise enzymatic steps leading to release of NAEs from NAPEs are unclear. Four different enzymatic routes have been proposed: 1) Direct hydrolytic cleavage of the phosphodiester bond of NAPE to release NAE, a reaction that is catalyzed by the NAPE-PLD enzyme (3). Although NAPE-PLD(-/-) mice possess reduced brain levels of longchain saturated NAEs, these animals do not display significant alterations in polyunsaturated NAE in the nervous system (including AEA). These findings invoke the existence of additional enzymatic routes for AEA formation in the brain. 2) Phospholipase-C-type cleavage of the phosphodiester bond releasing phospho-NAE, which is rapidly converted to NAE by a lipid phosphatase (11) . An enzyme displaying NAPE-phospholipase C-type activity remains to be identified, but a candidate phospho-NAE phosphatase, PTPN22, was cloned from RAW293 immune cells and is also expressed at low levels in the brain (13) . However, PTPN22(-/-) mice possess essentially wild-type levels of AEA in the brain (21). 3) Deacylation of NAPE to generate lysoNAPE which is then converted to NAE by a lysophospholipase D. Evidence for this pathway includes the identification of a secreted phospholipase, sPLA2 IB, that singly deacylates NAPE (22) . LysoNAPE generated by this enzyme was converted by brain extracts to NAE in a reaction presumed to be catalyzed by a Dtype lysophospholipase. More recent data suggest that this lysoNAPE-to-NAE transformation actually reflects a two-step conversion (see enzymatic route 4 ) (14). 4 ) Double-deacylation of NAPE to yield glycerophospho-(GP)-NAE, which is then converted to NAE by a metal-dependent phosphodiesterase. This pathway is supported by two principal observations. First, conversion of NAPE or (lyso)NAPE to NAE in NAPE-PLD(-/-) brains is blocked by MAFP, an inhibitor of serine hydrolases, including many A/B-type phospholipases. Similarly, an NAPE analog with non-hydrolyzable ether bonds in place of natural esters was not converted to NAE in NAPE-PLD(-/-) brain extracts, demonstrating the absolute requirement for NAPE deacylation (14) . Collectively, these observations suggest that double-O-deacylation, as would be performed by an MAFP-sensitive hydrolase, is required for the PLD-independent conversion of NAPE to NAE. This model was bolstered by the identification and molecular characterization of Abh4 as a B-type phospholipase selective for NAPEs over other phospholipid substrates. T h e resulting GP-NAE products are then rapidly converted by brain homogenates to NAEs by a metal-dependent phosphodiesterase. If this fourth enzymatic pathway is responsible for converting NAPEs to NAEs in brain, then this tissue should contain both the GP-NAE intermediates and a GP-NAE phosphodiesterase.
Here, we have identified the integral membrane enzyme GDE1 as a GP-NAE phosphodiesterase. GDE1 belongs to larger family of enzymes that hydrolyze the phosphodiester bond of glycerol-phosphodiesters releasing glycerolphosphate and a free alcohol. GDE domaincontaining enzymes are found in bacteria, yeast, plants, and mammals and are ascribed functions that include membrane remodeling, phospholipid turnover, and phosphate scavenging. To date, GDEs have been primarily characterized in the context of g l y c e r o p h o s p h o e t h a n o l a m i n e ( G P -E ) , g l y c e r o p h o s p h o c h o l i n e ( G P -C ) , o r glycerophosphoinositol (GP-I) metabolism (23) (24) (25) (26) .
To determine if any of the mammalian GDE-domain containing enzymes possess GP-NAE phosphodiesterase activity, we expressed these enzymes in COS-7 cells. Among the five GDEs tested, one enzyme, GDE1, exhibited robust activity with GP-NAE. GDE1 was originally identified in a yeast two-hybrid screen for proteins that interact with RGS16, a regulator of G-protein signaling (19) . Based on its interactions with RGS16, GDE1 is also referred to as MIR16 (for Membrane Interacting protein of RGS16). Subsequently GDE1 has been shown to cleave GP-inositol substrates in vitro, although the endogenous substrate(s) for this enzyme remain unknown (27). The Farquhar group went on to demonstrate that GPCR agonists could modulate the activity of GDE1 suggesting a provocative bidirectional interaction between GPCR signaling and GDE1 activity.
Several additional lines of biochemical evidence support GDE1 as the principal GP-NAE phosphodiesterase in brain tissue. First, GDE1 displayed a pH optimum and cation sensitivity nearly identical to those observed for brain GP-NAE phosphodiesterase activity. Both activities displayed slightly alkaline pH optima, inhibition by EDTA, calcium, and zinc, and activation by magnesium. Second, GDE1 is an integral membrane protein, which matches the subcellular distribution of the brain GP-NAE phosphodiesterase activity. Finally, the tissue distribution of GDE1 matched closely that of GP-NAE phosphodiesterase activity, as well as other enzymes involved in NAE metabolism, being highly expressed in brain and spinal cord, intermediately expressed in testes, kidney, and liver, and only weakly expressed in heart and spleen.
We have also reported herein the detection and quantification of GP-NAEs as endogenous brain constituents. To our knowledge, these lipids have not previously been reported as natural products in mammalian systems. Using liquid chromatography coupled with high-resolution tandem mass spectrometry we detected multiple GP-NAE species, including the proposed AEA precursor GPNArE, in normal mouse brain. These endogenous metabolites were detected at levels approximately 10-fold lower than NAEs suggesting a rapid enzymatic flux through this pathway. Consistent with this premise, substantial accumulation of endogenous GP-NAEs was observed upon incubation of brain lysates with the GP-NAE phosphodiesterase inhibitor EDTA. This accumulation was also blocked by MAFP, which presumably prevents the serine hydrolase (e.g., Abh4)-mediated sn-1/sn-2 deacylation of NAPE precursors. It is interesting to note that, the EDTAdependent accumulation of GP-NAEs was acylchain dependent. While significant increases were observed in long chain polyunsaturated (e.g., C20:4, C22:6), as well as shorter chain saturated and monounsaturated (e.g., C16:0, C18:1) GP-NAEs, no accumulation of the long chain saturated C20:0 GP-NAE was detected. We also detected a number of other long-chain saturated GP-NAEs (e.g., C22:0, C24:0, C24:1) in brain extracts that did not accumulate upon incubation with EDTA (data not shown). These findings presents a striking foil to the levels of NAEs in NAPE-PLD(-/-) mice, where significant decreases were observed exclusively in long chain (> C20) saturated/monounsaturated members of this lipid class (12) . Together, these data suggest that NAEs may be biosynthesized in vivo by a bifurcated pathway dependent on the identity of their acyl chains.
In summary, this work, in conjunction with previous studies (12, 14) , supports a model for AEA biosynthesis that involves double O-deacylation by Abh4 to yield GP-NArE followed by GDE1-mediated conversion of this lipid intermediated to AEA. Validation of this route for AEA biosynthesis through, for example, the creation of mice lacking Abh4 or GDE1, would designate these enzymes as principal regulators of endocannabinoid signaling in vivo and potential therapeutic targets for a range of human disorders, including obesity, smoking cessation, and cancer (28).
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Almaguer, C., Fisher, E., and Patton-Vogt, J. protein levels and GP-NAE phosphodiesterase activity. The ubiquitously expressed enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control to confirm integrity of tissue cDNA. Br -brain; Spc -spinal cord; Ht -heart; Lv -liver; Kd -kidney; Spln -spleen; Ts -testes. Figure 8 . N-acyl chain selectivity of GDE1. Membrane fractions from GDE1 transfected COS-7 cells were tested for activity against a panel of GP-NAE substrates bearing saturated (C16:0, C20:0), monounsaturated (C18:1) and polyunsaturated (C20:4, C22:6) N-acyl chains. Assays were performed with 100 µM of each substrate using LC-MS to measure release of NAE.
Supplemental Figure 1 . Specificity of rabbit polyclonal anti-mGDE1 antibodies. GDE1-and mocktransfected COS-7 cell membranes were treated with or without PNGase F and probed with anti-mGDE1 antibodies using standard western blotting procedures. A 35-40 kDa doublet was detected exclusively in GDE1-transfected cells that shifted to a single 35 kDa protein after PNGase F digestion. at The Scripps Research Institute on March 5, 2008 
